{"id":"live-attenuated-zoster-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This immune response helps the body recognize and fight the virus, providing protection against shingles. The vaccine is made from a live but weakened virus, which is unable to cause disease but still triggers an immune response.","oneSentence":"The live attenuated zoster vaccine works by introducing a weakened form of the varicella-zoster virus to stimulate an immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:11.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles)"}]},"trialDetails":[{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT04089930","phase":"","title":"Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2020-06-01","conditions":"Lupus Erythematosus","enrollment":68},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127},{"nctId":"NCT00681031","phase":"PHASE4","title":"Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-14","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Immunosenescence, Shingles","enrollment":33},{"nctId":"NCT03314103","phase":"PHASE3","title":"Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-10-06","conditions":"Herpes Zoster","enrollment":30000},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160},{"nctId":"NCT02329457","phase":"PHASE2, PHASE3","title":"VZV Vaccine for Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Varicella Zoster Infection","enrollment":100},{"nctId":"NCT03114943","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2016-07-14","conditions":"Varicella","enrollment":516},{"nctId":"NCT01573182","phase":"PHASE2","title":"Herpes Zoster Vaccine for Bone Marrow Transplant Donors","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2012-04","conditions":"Herpes Zoster","enrollment":8},{"nctId":"NCT02692066","phase":"","title":"Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2016-04","conditions":"Varicella, Transplants","enrollment":""},{"nctId":"NCT02408159","phase":"PHASE4","title":"Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy","status":"TERMINATED","sponsor":"Innovaderm Research Inc.","startDate":"2016-06","conditions":"Psoriasis","enrollment":3},{"nctId":"NCT03121638","phase":"PHASE1","title":"Safety Study of NBP608 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2012-11","conditions":"Varicella Zoster, Immunization; Infection","enrollment":150},{"nctId":"NCT03120364","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-09-09","conditions":"Herpes Zoster","enrollment":824},{"nctId":"NCT03116594","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-01-03","conditions":"Herpes Zoster","enrollment":675},{"nctId":"NCT03114982","phase":"PHASE2","title":"The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-05","conditions":"Varicella","enrollment":152},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Shingles","enrollment":22439},{"nctId":"NCT00005009","phase":"PHASE1","title":"Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-02","conditions":"Kidney Transplant Recipients","enrollment":7},{"nctId":"NCT01137669","phase":"PHASE1","title":"ZOSTAVAX® in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":34},{"nctId":"NCT02514018","phase":"PHASE4","title":"Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-09","conditions":"Healthy","enrollment":45},{"nctId":"NCT02526745","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2015-12","conditions":"Herpes Zoster","enrollment":440},{"nctId":"NCT00007501","phase":"PHASE3","title":"Shingles Prevention Study","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1998-11","conditions":"Herpes Zoster, Postherpetic Neuralgia","enrollment":38456},{"nctId":"NCT00830648","phase":"PHASE4","title":"Safety of a Second Dose of Biken's Varicella Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-01","conditions":"Varicella","enrollment":122},{"nctId":"NCT01064141","phase":"PHASE2","title":"A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":210},{"nctId":"NCT01356004","phase":"PHASE4","title":"Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-01","conditions":"Psoriasis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"live attenuated zoster vaccine","genericName":"live attenuated zoster vaccine","companyName":"Changchun BCHT Biotechnology Co.","companyId":"changchun-bcht-biotechnology-co","modality":"Biologic","firstApprovalDate":"","aiSummary":"The live attenuated zoster vaccine works by introducing a weakened form of the varicella-zoster virus to stimulate an immune response. Used for Prevention of herpes zoster (shingles).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}